Edition:
United Kingdom

Biotechnology & Medical Research

Page 1

Ablynx to offer and sell about $175 million of its ordinary shares

Tuesday, 17 Oct 2017

Oct 17 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING.‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​.‍BOFA MERRILL LYNCH, J.P. MORGAN AND JEFFERIES ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR OFFERING​.‍INVESTORS OTHER THAN QUALIFIED INVESTORS UNDER APPLICABLE LAW WILL NOT BE ELIGIBLE TO PARTICIPATE IN THIS PRIVATE PLACEMENT​.‍BAIRD, BRYAN, GARNIER & CO. AND LADENBURG THALMANN ARE ACTING AS CO-MANAGERS FOR OFFERING​.‍FINAL PRICE PER SHARE OF ORDINARY SHARES TO BE DETERMINED FOLLOWING BOOKBUILDING PROCESS​.

Immune Design says it may offer shares of up to $50 mln

Monday, 3 Jul 2017

July 3 (Reuters) - Immune Design Corp :Immune design corp - ‍immune design corp. Entered into a sales agreement with cowen and company, llc​.Immune design corp - ‍co may offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $50 million​.Immune design corp - co may offer and sell, from time to time at its sole discretion through cowen, as its sales agent, shares of its common stock​.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary